

## **Effect of omega-3 LCPUFA supplementation on maternal fatty acid and oxylipin concentrations during pregnancy**

K P Best<sup>1,2</sup>, R A Gibson<sup>1,3</sup>, L N Yelland<sup>1,4</sup>, S Leemaqz<sup>1</sup>, J Gomersall<sup>1,4</sup>, G Liu<sup>1</sup>, M Makrides<sup>1,2</sup>

### **Authors' affiliations:**

<sup>1</sup>South Australian Health and Medical Research Institute, SAHMRI Women and Kids, North Terrace, Adelaide SA

<sup>2</sup>School of Medicine, University of Adelaide, North Terrace, Adelaide SA

<sup>3</sup>School of Agriculture, Food and Wine, University of Adelaide, North Terrace, Adelaide SA

<sup>4</sup>School of Public Health, University of Adelaide, North Terrace, Adelaide SA

### **Corresponding author:**

Dr Karen Best

SAHMRI Women and Kids Theme

South Australian Health and Medical Research Institute (SAHMRI)

Women's and Children's Hospital, Level 7, 72 King William Road, North Adelaide, South Australia 5006

T: +61 8 8128 4416

E: karen.best@sahmri.com

**Keywords:** Omega-3 fatty acids, docosahexaenoic acid, oxylipins, polyunsaturated fatty acids, pregnancy.

**Abbreviations used:** AA, arachidonic acid; ALA, alpha linolenic acid; DBS, dried blood spot; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid, EPA, eicosapentaenoic acid; FAME, fatty acid methyl esters; LA, linolenic acid; LC-MS-MS, Liquid Chromatography with tandem mass spectrometry; LCPUFA, long chain polyunsaturated fatty acid; ORIP, Omega-3 fats to Reduce the Incidence of Prematurity; PUFA, polyunsaturated fatty acids.

1 **ABSTRACT**

2 **Introduction:** Omega-3 long chain polyunsaturated fatty acids (LCPUFA) have been associated with  
3 a reduction in risk for preterm birth. However, there is limited understanding of how fatty acids and  
4 their bioactive derivatives (oxylipins) change over the course of pregnancy. Here we document the  
5 changes in concentration of fatty acids and oxylipins during pregnancy and how fatty acid status and  
6 oxylipin concentrations are affected by supplementation with omega-3 LCPUFA. We also investigate  
7 the degree to which fatty acid and oxylipin changes across pregnancy are influenced by baseline  
8 omega-3 status.

9 **Materials and Methods:** We profiled the fatty acids in all lipids in dried blood spots (total blood  
10 fatty acids) by gas chromatography and free (unesterified) fatty acids and their associated oxylipins in  
11 separate dried blood spot samples by LC-MS-MS collected from a random sample of 1263 women  
12 with a singleton pregnancy who participated in the ORIP (Omega-3 fats to Reduce the Incidence of  
13 Prematurity) trial. ORIP is a double-blind, randomized controlled trial involving 5544 participants and  
14 designed to determine the effect of supplementing the diets of pregnant women with omega-3  
15 LCPUFA on the incidence of early preterm birth. Maternal whole blood finger prick samples were  
16 collected at baseline (~14 weeks gestation) and at completion of the study intervention period (34  
17 weeks gestation).

18 **Results:** The concentration of most total and free polyunsaturated fatty acids and their associated  
19 oxylipins declined over the course of pregnancy. Omega-3 LCPUFA supplementation increased total  
20 DHA and 7-HDHA and mitigated the decline in free DHA, 4-HDHA and 14-HDHA. The intervention  
21 had minimal or no effect on free EPA, LA, AA and their associated oxylipins. Omega-3 LCPUFA  
22 supplementation in women with higher omega-3 status at baseline was associated with a significant  
23 increase in 7-HDHA and 4-HDHA between the treatment and control whereas there were no  
24 differences between groups in 7-HDHA and 4-HDHA in women with intermediate or lower baseline  
25 omega-3 status.

26 **Conclusion:** Our data suggest a differential response with or without omega-3 supplementation for  
27 DHA and DHA-derived oxylipins, which may have an important role to play in modulating pregnancy  
28 duration. Further work is needed to understand their role, which may allow us to better tailor omega-3  
29 supplementation for preterm birth prevention.

## 30 1. Introduction

31 There is strong evidence to support maternal supplementation with omega-3 long chain  
32 polyunsaturated fatty acids (LCPUFAs) to reduce the risk of preterm birth [1, 2]. Some of the pro- or  
33 anti-inflammatory effects of LCPUFAs can be attributed to their oxidized products, collectively  
34 known as oxylipins. Oxylipins comprise a large, heterogeneous family of bioactive mediators that  
35 have essential roles in normal physiology and function [3]. Synthesis usually occurs via the  
36 cyclooxygenase, lipoxygenase or cytochrome P450 pathways [4] and alterations in oxylipin  
37 concentrations have been described for numerous diseases in human and animal models [5-9].

38 During pregnancy, oxylipins are known to alter the function of the placenta, vascular and immune  
39 responses [9-11], yet little is known about how total and free fatty acid and oxylipin levels change  
40 during pregnancy. Our recent secondary analysis of singleton pregnancies in the ‘Omega-3 fats to  
41 Reduce the Incidence of Prematurity’ (ORIP) trial, suggests that the sum of all omega-3 fatty acids  
42 (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA] + docosapentaenoic acid [DPA] + alpha  
43 linolenic acid [ALA]) in whole blood lipids in early pregnancy, is the strongest biomarker to predict  
44 early preterm birth. We found that women with a low omega-3 baseline status ( $\leq 4.1\%$  of total fatty  
45 acids) are at higher risk of early preterm birth (<34 weeks gestation) and that this risk can be reduced  
46 by omega-3 LCPUFA supplementation. However, the data also suggest that supplementing mothers  
47 who are already replete in omega-3 ( $> 4.9\%$  total fatty acids) with additional omega-3 LCPUFA,  
48 significantly increases the risk of early preterm birth [12]. Because of the high biological activity of  
49 LCPUFAs and their derived oxylipins [13-15], we sought to determine whether omega-3 LCPUFA  
50 supplementation leads to oxylipin changes that may be critical to prevent preterm birth.

51 Using maternal fatty acid status data from blood collected from singleton pregnancies at entry to our  
52 ORIP trial (~14 weeks’ gestation), we explored the changes in concentration of whole blood lipid  
53 fatty acids, free fatty acids and oxylipins during pregnancy from around 14 to 34 weeks’ gestation.  
54 Here we describe differences between women who were supplemented with omega-3 LCPUFA and  
55 non-supplemented women in the control group. Because the ORIP Trial intervention contained 90%  
56 DHA and 10% EPA, our analyses focused on these omega-3 LCPUFA. Since it is possible that some

57 interconversion of omega 3 fatty acids occurred, we examined changes in whole blood lipid omega-3  
58 status (sum of all omega-3 fatty acids; DHA, EPA, DPA and ALA) and free omega-3 fatty acids. Key  
59 competitive omega-6 fatty acids, arachidonic acid (AA) and linolenic acid (LA) were also examined.  
60 In particular, to explore differential effects of omega-3 LCPUFA supplementation in pregnancy [12],  
61 we also report the degree to which the baseline omega-3 status altered the changes in the  
62 concentration of free fatty acids and oxylipins over time with treatment.

## 63 **2. Participants and Methods**

64

### 65 *2.1. ORIP Trial - Sample Collection*

66 The ORIP trial was a multicenter, double-blind, randomized controlled trial designed to determine the  
67 effect of supplementing the diets of pregnant women with omega-3 LCPUFA on the incidence of  
68 early preterm birth [16, 17]. The ORIP trial primary results have been previously published [17].  
69 Women were recruited to the ORIP trial prior to 20 weeks' gestation, with few exclusions, including  
70 those who had been regularly consuming a low dose DHA supplement ( $\leq 150$  mg per day) and were  
71 willing to cease. A total of 5544 women were randomized to receive either  $\approx 900$  mg omega-3  
72 LCPUFA (3 x DHA enriched fish oil/day ( $\approx 800$  mg DHA and  $\approx 100$  mg eicosapentaenoic acid  
73 (EPA)/day)) or isocaloric vegetable oil control capsules with trace fish oil for masking ( $\approx 15$  mg DHA  
74 and  $\approx 4$  mg EPA/day) until 34 weeks of gestation. A finger prick blood sample was collected from  
75 participants on to chemically treated filter paper as two dried blood spots [18] at baseline ( $\sim 14$   
76 weeks') and 34 weeks' gestation [17]. A simple random sample of 1382 ORIP women were selected  
77 for further detailed analyses.

78 The present study reports findings from additional analyses of dried blood spot samples to measure  
79 concentration of fatty acids and their associated oxylipins among women in this random sample who  
80 had a singleton pregnancy. Measures in maternal capillary whole blood, collected at  $\sim 14$  and 34  
81 weeks' gestation, are reported in **Supplementary Table 1**.

82

83        2.2. *Laboratory Analysis*

84        All fatty acid analyses were undertaken in the fatty acid laboratory at the School of Agriculture and  
85        Wine, University of Adelaide. Briefly, the dried blood spot on a chemically treated paper (18) was  
86        treated as follows:

87        For total fatty acids (the complete fatty acid spectrum from all lipids in blood), the first blood spot  
88        was placed in a 6mL vial (Wheaton, Millville, USA) with 2 mL of 1% (v/v) H<sub>2</sub>SO<sub>4</sub> (18M, AR grade,  
89        BDH, Sussex, UK) in anhydrous methanol (Merck, Darmstadt, Germany), sealed and heated at 70°C  
90        for 3 hours. The resultant fatty acid methyl esters (FAME) were extracted into heptane (Merck,  
91        Darmstadt, Germany). FAME were separated and quantified using an Agilent 7890 Gas  
92        Chromatograph (Agilent, CA, USA) equipped with a BPX70 capillary column 30 m x 0.25 mm, film  
93        thickness 0.25 µm (Trajan Pty Ltd., Victoria, Australia), programmed temperature vaporization  
94        injector (at 250°C) and a flame ionization detector (at 300°C). A programmed temperature ramp (140-  
95        240°C) was used. Helium gas was utilized as a carrier at a flow rate of 1 mL/min in the column and  
96        the inlet split ratio was set at 20:1. The FAME were identified and quantified by comparing the  
97        retention times and peak area values of unknown samples to those of commercial lipid standards (Nu-  
98        Chek Prep Inc., Elysian, MN, USA) using the Agilent Chemstation data system.

99        For free fatty acids (non-esterified fatty acids) and their oxylipins, a 6 mm disc of blood was obtained  
100        from the second dried blood spot and placed into a separated well in a 96-well plate with extraction  
101        solvent (150 µL of 80% aqueous methanol) containing deuterated internal standards (d<sub>5</sub>-DHA, d<sub>8</sub>-  
102        AA, d<sub>5</sub>-EPA, d<sub>4</sub>-LA, d<sub>8</sub>-12S-HETE, d<sub>4</sub>-LTB<sub>4</sub> and d<sub>4</sub>-13S-HODE). The plate was covered and gently  
103        shaken on a plate shaker for 30 min at room temperature, and the extract was analyzed using an  
104        Agilent 1290 infinity ultra-high-performance liquid chromatography equipped with AB SCIEX 5500  
105        triple quadrupole tandem mass spectrometer, using electrospray ionisation in negative mode. The  
106        mass spectrometer had the following conditions: nitrogen was used as the source gas; curtain gas and  
107        collision gas were set at 20 and 6 arbitrary units, respectively; capillary voltage was -4500 V;  
108        entrance potential was set at -10 V and temperature was set at 200 °C [19, 20].

109        *2.3. Statistical Analysis*

110        A separate analysis was performed for each fatty acid and oxylipin. The analysis was performed on  
111        the available data and any values below the limit of detection were set to half the limit of detection.  
112        The data were analyzed using a linear model including treatment group, time point and their  
113        interaction, with adjustment for the randomization strata (enrolment center and recent omega-3  
114        supplementation). Clustering due to repeated measurements over time was taken into account using  
115        generalized estimating equations with an exchangeable working correlation structure. Post hoc  
116        comparisons were performed to test whether there were changes in the concentration of the fatty acids  
117        and oxylipins over time (34 weeks' vs baseline) separately within each group, and whether there were  
118        differences between the groups in the changes in concentration over time (omega-3 change over time  
119        vs control change over time). Statistical significance was assessed at the  $P < 0.05$  level and 95%  
120        confidence intervals were calculated for all estimated effects, without adjustment for multiple  
121        comparisons.

122        A sensitivity analysis was performed using multilevel tobit regression models, where values below the  
123        limit of detection were treated as censored. The multilevel tobit regression approach was chosen to be  
124        a sensitivity analysis, rather than the primary analysis, due to the small number of oxylipins affected,  
125        the generally small percentage of values below the limit of detection, and concerns over the constant  
126        variance assumption required for the multilevel tobit regression model.

127        Exploratory analyses were performed for DHA and total omega-3 fatty acids to investigate whether  
128        the changes in the concentration of fatty acids and oxylipins over time within each treatment group  
129        and the differences between treatment groups depended on baseline omega-3 status. Women were  
130        categorized as having low ( $\leq 4.1\%$ ), moderate ( $> 4.1$  to  $\leq 4.9\%$ ) or high ( $> 4.9\%$ ) baseline omega-3  
131        status, corresponding to subgroups where omega-3 LCPUFA supplementation has been shown to  
132        significantly reduce the risk, have no significant effect, or significantly increase the risk of early  
133        preterm birth, respectively [12]. The analysis model included treatment group, time point, baseline  
134        omega-3 status category and all 2 and 3-way interactions. Post hoc comparisons were performed to

135 test for differences between the high and low status categories ( $>4.9\%$  vs  $\leq 4.1\%$ ) in the change over  
136 time within groups and the difference between groups in these changes over time. All analyses were  
137 performed using R version 3.6.2.

### 138 **3. Results**

139

#### 140 *3.1. Characteristics of the study population*

141 Of the 5544 women enrolled in the ORIP Trial, 1382 women were randomly selected to have their  
142 blood samples undergo further analysis to determine fatty acid and oxylipin concentrations. This  
143 report presents findings for the 1263 women in this random sample who had a singleton pregnancy  
144 and baseline dried blood spot data, of which 1023 (81%) also had a dried blood spot sample at 34  
145 weeks' gestation, **Figure 1**. Descriptive analyses showed that women in both groups had comparable  
146 baseline characteristics and fatty acid profiles as expected due to randomization, **Table 1**. Oxylipins at  
147 baseline were also similar by group, as shown in **Supplementary Table 2**.

#### 148 *3.2. Changes in concentration of fatty acids and oxylipins over time and between groups*

149 The concentration of most fatty acids and oxylipins changed significantly over pregnancy in both the  
150 omega-3 LCPUFA and control groups. While the concentration of most fatty acids and oxylipins  
151 decreased with gestational age, some increases were observed.

#### 152 **Omega-3 Fatty Acid Results**

##### 153 *3.2.1. DHA*

154 Total DHA decreased during pregnancy in the control group. This was more than offset by  
155 supplementation with omega-3 LCPUFA. In contrast, free DHA decreased over pregnancy in  
156 both groups, but the drop was significantly smaller in the omega-3 LCPUFA group. This  
157 pattern seen for free DHA was mirrored for oxylipins 4-HDHA and 14-HDHA, while 7-HDHA  
158 followed the same pattern as total DHA. Omega-3 intervention had no significant effect on the  
159 change over pregnancy in 19,20 EpDPA, **Figure 2**.

160 3.2.2. EPA

161 Total EPA decreased significantly over the course of pregnancy, and this was largely ablated by  
162 the omega-3 LCPUFA intervention. The changes in free EPA during pregnancy largely  
163 reflected those seen in the total EPA with the omega-3 intervention maintaining baseline levels.  
164 There was no effect of omega-3 LCPUFA supplementation on the EPA derived oxylipin 18-  
165 HEPE, with both groups showing a significant decline over pregnancy **Figure 3**.

166 3.2.3. Omega-3 Fatty Acids Status

167 The sum of the omega-3 fatty acids in the lipids in dried blood spot (ALA, EPA, DPA and  
168 DHA) decreased in the control group from baseline to 34 weeks but increased in the omega-3  
169 LCPUFA supplemented group. The aggregate of free omega-3 fatty acids declined with  
170 gestational age in both groups, though the decline was larger in the control group **Figure 6**.

171 **Omega-6 Fatty Acid Results**

172 3.2.4. AA

173 Both total blood lipid AA and free AA declined between baseline and 34 weeks' gestation, with  
174 a larger decline seen in the omega-3 LCPUFA group. While AA oxylipin derivatives  
175 significantly rose or fell over pregnancy, no differences were observed between the groups  
176 **Figure 4**.

177 3.2.5. LA

178 There was a small but significant reduction in total blood lipid LA in the control group over the  
179 course of pregnancy which was negated by omega-3 LCPUFA treatment. In contrast, free LA  
180 increased with gestational age in both groups. However, all LA derived oxylipins decreased  
181 over pregnancy independently of the treatment groups **Figure 5**.

182 Further details, including estimated effects and 95% confidence intervals, can be found in  
183 **Supplementary Table 3**. Similar results were obtained in the sensitivity analysis (data not shown).



184           3.2.6. *Effect of baseline omega-3 status on DHA and associated oxylipins*

185    We previously reported that the effects of omega-3 LCPUFA supplementation on early preterm birth  
186    could be categorized by omega-3 status at baseline (early pregnancy ~14 weeks gestation) [12]. For  
187    the random cohort reported here, there were 195 (15.4%) women with a baseline omega-3 status of  
188     $\leq 4.1\%$  (low baseline status); 518 (41.0%)  $>4.1$  to  $\leq 4.9\%$  (moderate baseline status), and 550 women  
189    (43.5%)  $>4.9\%$  (high baseline omega-3 status). Baseline omega-3 status significantly influenced the  
190    effects of omega-3 LCPUFA supplementation on changes over pregnancy for 7-HDHA and the  
191    aggregate of free omega-3 fatty acids (interaction  $P < 0.05$ ), **Table 2**. 7-HDHA showed a decline over  
192    pregnancy across the three categories of baseline omega-3 status within the control group. Omega-3  
193    LCPUFA supplementation resulted in no significant change in 7-HDHA over the course of pregnancy  
194    for categories  $\leq 4.1\%$  and  $>4.1$  to  $\leq 4.9\%$ , but an increase in women with high baseline status  $>4.9\%$ ,  
195    leading to a significant difference between the groups in this baseline category. A similar pattern was  
196    also observed for 4-HDHA (interaction  $P < 0.06$ ). Free omega-3 decreased over time in both groups  
197    across all three categories of baseline omega-3 status. However, omega-3 LCPUFA supplementation  
198    resulted in significantly smaller decreases over time among women with moderate or high omega-3  
199    baseline status, **Table 2**. Additional post hoc comparisons testing for differences between women with  
200    high and low baseline status ( $>4.9\%$  vs  $\leq 4.1\%$ ) showed that differences in the change over pregnancy  
201    between the groups were significantly larger among women with high compared to low baseline  
202    status for free DHA, 4-HDHA, 7-HDHA and the sum of free omega-3 fatty acids, **Supplementary**  
203    **Table 4** and **Supplementary Figures 1 to 4**.

204    **4. Discussion and Conclusions**

205    We anticipated that omega-3 LCPUFA supplementation would mostly affect DHA and DHA-derived  
206    oxylipins rather than EPA and EPA-derived oxylipins, because of the small dose of EPA included in  
207    the study intervention. We also assumed that supplementation of women with an oil blend rich in  
208    DHA would increase the levels of DHA and its metabolites in dried blood spots. Thus, the increased  
209    total blood lipid DHA, 7-HDHA, and 19,20 EpDPA due to supplementation seemed logical. We had

210 not anticipated the fact that several of the oxygenated metabolites of DHA naturally declined over the  
211 assessed 20-week period of gestation. However, omega-3 LCPUFA supplementation reduced the  
212 declines of free DHA, 4-HDHA, and 14-HDHA between the end of the first trimester of pregnancy  
213 and 34 weeks of gestation so that overall the effect of supplementation was consistent in that there  
214 was an overall increase in DHA and its various metabolites relative to no supplementation.

215 Although early preterm births would have occurred between the two sampling periods in our study  
216 (14 and 34 weeks of gestation) we nevertheless considered it important to understand these  
217 biochemical data in the context of the clinical outcomes from the ORIP trial. Interestingly, secondary  
218 analyses of the ORIP Trial showed that the benefit of omega-3 LCPUFA supplementation on reducing  
219 the risk of early preterm birth was limited to women with low baseline omega-3 status ( $\leq 4.1\%$ );  
220 women who already had a higher baseline status of omega-3 fatty acids ( $> 4.9\%$ ) and who were  
221 supplemented with additional DHA, increased their risk of early preterm birth [12]. Thus, it is  
222 pertinent to explore the relationships between changes in oxylipins recorded here according to these  
223 measures of omega-3 status. In particular, whether the changes in oxylipins in relation to baseline  
224 measures and effects of omega-3 LCPUFA supplementation could explain the apparently  
225 contradictory effects of supplementation on clinical outcomes. Namely, why omega-3 LCPUFA  
226 supplementation lowered the risk of early preterm birth in women with low omega-3 status at  
227 baseline, while the same treatment increased the risk of early preterm birth in women with high  
228 omega-3 status at baseline. Our data demonstrated that it was the 5-lipoxygenase derivatives, 7-  
229 HDHA and 4-HDHA, whose response to omega-3 LCPUFA supplementation was influenced by the  
230 baseline omega-3 status. Omega-3 LCPUFA supplementation in women with higher omega-3 status at  
231 baseline was associated with a significant increase in 7-HDHA and 4-HDHA between treatment and  
232 control whereas there were no differences between groups in 7-HDHA and 4-HDHA in women with  
233 moderate or low omega-3 status. It is therefore feasible that the increase in the 5-lipoxygenase  
234 derivatives associated with DHA supplementation in women with already high omega-3 fatty acid  
235 status may be causally related to the increased risk of early preterm birth in these women. However,  
236 there was no evidence of 7-HDHA and 4-HDHA being affected by omega-3 LCPUFA

237 supplementation in women with low omega-3 status, where risk of early preterm birth was high, and  
238 supplementation effectively lowered this risk. Further exploration is needed to understand the role of  
239 5-lipoxygenase products as well as other oxylipins in determining the timing of birth at both high  
240 and low baseline omega-3 status.

241 The changes seen in the current report were consistent with a much smaller study also nested within  
242 the ORIP trial that involved plasma samples (rather than whole blood from dried blood spots)  
243 collected at trial entry (end of the first trimester) and 24 weeks of gestation, indicating that the  
244 observed changes happen relatively quickly [21]. The clinical significance of these changes is yet to  
245 be fully determined, although this earlier study [21] did hypothesize that higher 5-lipoxygenase  
246 derivatives of both DHA and AA in early to mid-pregnancy were associated with increased risk of  
247 spontaneous preterm birth.

248 Traditionally, the timing of parturition has been discussed in terms of cyclooxygenase products,  
249 largely involving a preponderance of the AA derivatives PGE2 and PGF2 $\alpha$ , with the equivalent  
250 derivatives from EPA being significantly less potent [9, 22, 23]. Our technology was not sensitive  
251 enough to accurately detect these cyclooxygenase products in the collected dried blood spots,  
252 although the pattern of change of a related prostaglandin (PGD2) across pregnancy did not differ  
253 between the omega-3 LCPUFA and control groups.

254 Surprisingly, our data showed very little, if any, difference in the pattern of change of total lipid and  
255 free omega-6 AA and LA between omega-3 supplemented and control groups, and this lack of  
256 difference also resulted in no differences between groups in their measured oxylipin derivatives. In  
257 non-pregnant adults and lactating women, the equivalent omega-3 LCPUFA supplementation with  
258 800mg DHA would be expected to reduce blood AA levels by more than the small reduction observed  
259 in this study [24]. It may be that the hormonal and hemodynamic changes that occur over the course  
260 of pregnancy are partially designed to maintain an AA-associated homeostasis. Interestingly, from the  
261 oxylipins assessed it was only three AA derived oxylipins, which are 5-lipoxygenase products (5-

262 HETE, LXA4, LXB4), that naturally increased over the course of pregnancy regardless of omega-3  
263 supplementation. .

264 Our study had several strengths. It was nested in a randomized controlled trial, had large numbers and  
265 matched fatty acids in total blood lipids with the free fatty acid pool and their derived oxylipins,  
266 providing us with some important insights into how fatty acids and oxylipins change over the course  
267 of pregnancy, and how this trajectory is influenced by omega-3 LCPUFA supplementation. A study  
268 such as this would have been more difficult logistically and more costly without the use of the dried  
269 blood spot technology, although we were not able to consistently detect the cyclooxygenase products.  
270 The main limitation is that we were not able to reliably link the fatty acid and oxylipin changes  
271 between 14 and 34 weeks of gestation directly with prematurity, as we would have missed all the  
272 preterm births occurring before 34 weeks of gestation.

273 In summary, this is a large and comprehensive study to document fatty acid and oxylipin changes  
274 across pregnancy. We demonstrated that most fatty acids in both total blood lipid and free fatty acid  
275 fractions and their associated oxylipins decline over the course of pregnancy, with a few notable  
276 exceptions related to 5-lipoxygenase products. Omega-3 LCPUFA supplementation mostly arrested  
277 the declines in free DHA and DHA-derived oxylipins, with a suggestion of a differential response in  
278 the 5-lipoxygenase products depending on the baseline omega-3 status of women. Our work has  
279 added to the speculation that 5-lipoxygenase products have an important role to play in modulating  
280 pregnancy duration. Further work to understand their role will allow us to better tailor treatments for  
281 women to achieve optimal pregnancy outcomes.

282 **Acknowledgements**

283 We thank the women and their families for their participation in the original study.

284 **Disclosure of Interests:**

- 285 • Dr. Gibson received supplies from Croda UK, prepared supplies for the ORIP trial for  
286 Efamol/Wassen UK.
- 287 • Dr Gibson and Dr Liu hold a patent (WO2013/10 40 25 A1) on stabilizing and analyzing fatty  
288 acids in a biologic sample stored on solid media, owned by Adelaide Research and Innovation,  
289 the University of Adelaide, and licensed to Xerion.
- 290 • Dr. Makrides received supplies from Croda UK, and prepared supplies for the ORIP trial for  
291 Efamol/Wassen UK.
- 292 • Dr. Best, Dr Yelland, Dr Leemaqz and Dr. Gomersall have no conflicts of interest to disclose.

293 **Contribution to Authorship:** RAG and MM, conceived the analysis. KPB, RAG, LNY, JG and MM  
294 were involved in the analysis and interpretation of data and SL and LNY carried out the statistical  
295 analyses. KB drafted the manuscript and all authors critically revised and edited the manuscript and  
296 approved the final submitted version. All authors take responsibility for the integrity of the data and  
297 the accuracy of the data analysis.

298 **Funding:** The original study was supported by grants from the National Health and Medical Research  
299 Council (NHMRC) (1050468) and the Thyne Reid Foundation, and fellowships awarded to M  
300 Makrides (1061704), RA Gibson (1046207) and LN Yelland (1052388) from the NHMRC. The  
301 secondary analysis was supported by the National Health and Medical Research Council Centre of  
302 Research Excellence in Targeted Nutrition to Improve Maternal and Child Health Outcomes  
303 (1135155). KP Best was supported by a Women's and Children's Hospital Foundation, MS McLeod  
304 Fellowship.

**Figure 1. Flowchart of participants in the ORIP trial and the data available for this exploratory analysis.**

DBS, dried blood spot; LCUPA, long chain polyunsaturated fatty acid; ORIP, Omega-3 fats to Reduce the Incidence of Prematurity

**Figure 2. Effect of treatment group and time on concentration of DHA and associated oxylipins**

DHA, docosahexaenoic acid

Data points are mean fatty acid and oxylipin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by \*  $P < 0.05$ , \*\*  $P < 0.01$  and \*\*\*  $P < 0.0001$ .

**Figure 3. Effect of treatment group and time on concentration of EPA and associated oxylipins**

EPA, eicosapentaenoic acid.

Data points are mean fatty acid and oxylipin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by \*  $P < 0.05$ , \*\*  $P < 0.01$  and \*\*\*  $P < 0.0001$ .



**Figure 4. Effect of treatment group and time on concentration of Omega-3**

‘Omega-3’, sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.

Data points are mean fatty acid and oxylipin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by \*  $P < 0.05$ , \*\*  $P < 0.01$  and \*\*\*  $P < 0.0001$ .

**Figure 5. Effect of treatment group and time on concentration of AA and associated oxylipins**

AA, Arachidonic acid.

Data points are mean fatty acid and oxylipin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by \*  $P < 0.05$ , \*\*  $P < 0.01$  and \*\*\*  $P < 0.0001$ .

**Figure 6. Effect of treatment group and time on concentration of LA and associated oxylipins**

LA, linoleic acid.

Data points are mean fatty acid and oxylipin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by \*  $P < 0.05$ , \*\*  $P < 0.01$  and \*\*\*  $P < 0.0001$ .

**Table 1. Baseline Characteristics of women included in the analysis by treatment group**

<b>Characteristic</b>	<b>Omega-3 (N=614)</b>	<b>Control (N=649)</b>	<b>Total (n=1263)</b>
Consumed omega-3 containing supplements in the previous 3 mo: n(%)	89 (14.5)	85 (13.1)	174 (13.8)
Maternal age: Median (IQ range)	30.0 (27.0-34.0)	30.0 (27.0-34.0)	30.0 (27.0-34.0)
Gestation: Median (IQ range)*	14.0 (12.6-16.1)	14.1 (12.7-16.4)	14.0 (12.7-16.3)
Mother was primiparous: n/N(%)	280/614 (45.8)	280/648 (43.2)	560/1260 (44.4)
Maternal weight at trial entry: Median (IQ range)**	69.0 (60.0-81.0)	69.0 (60.4-81.4)	69.0 (60.0-81.0)
Maternal white race: n/N(%)	456/614 (74.3)	456/648 (70.4)	912/1262 (72.3)
Mother completed a high-school education: n/N(%)	506/612 (82.7)	499/647 (77.1)	1005/1259 (79.8)
Mother smoked cigarettes at trial entry or leading up to pregnancy: n/N(%)	95/612 (15.5)	101/648 (15.6)	196/1260 (15.6)
Mother drank alcohol at trial entry or leading up to pregnancy: n/N(%)	356/612 (58.2)	362/648 (55.9)	718/1260 (57.0)
Mother had previous preterm delivery: <37 wk of gestation: n/N(%)	37/612 (6.0)	39/648 (6.0)	76/1260 (6.0)
Maternal DHA level (% of total fatty acids): Median (IQ range)	2.7 (2.3-3.1)	2.7 (2.3-3.1)	2.7 (2.3-3.1)
Male fetus: n/N(%)	315/605 (52.1)	317/636 (49.8)	632/1241 (50.9)
Fatty acid status			
- Total DHA: Mean (SD)	2.7 (0.6)	2.8 (0.7)	2.7 (0.6)
- Free DHA: Mean (SD)	0.9 (0.5)	0.9 (0.4)	0.9 (0.5)
- Total EPA: Mean (SD)	0.5 (0.2)	0.5 (0.2)	0.5 (0.2)
- Free EPA: Mean (SD)	0.1 (0.1)	0.1 (0.1)	0.1 (0.1)
- Omega-3 <sup>†</sup> : Mean (SD)	4.9 (0.8)	4.9 (1.0)	4.9 (0.9)
- Free Omega-3 <sup>†</sup> : Mean (SD)	1.1 (0.6)	1.1 (0.5)	1.1 (0.6)
- Total LA: Mean (SD)	19.4 (2.5)	19.3 (2.5)	19.3 (2.5)
- Free LA: Mean (SD)	3.8 (2.5)	3.8 (2.1)	3.8 (2.3)
- Total AA: Mean (SD)	8.2 (1.2)	8.2 (1.2)	8.2 (1.2)
- Free AA: Mean (SD)	1.2 (0.7)	1.2 (0.6)	1.2 (0.6)

\* Data were missing for 2 pregnancies in the Omega-3 group.

\*\* Data were missing for 11 pregnancies in the Omega-3 group and 19 in the Control group.

<sup>†</sup>Omega-3 fatty acids, sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.

**Table 2: Effect of baseline omega-3 status, treatment group and time on concentration of DHA, DHA derived oxylipins and omega-3 fatty acids<sup>†</sup>**

<b>Baseline Omega-3<sup>†</sup> Status</b>	<b>Omega-3 Group Baseline Mean (SD)</b>	<b>Control Group Baseline Mean (SD)</b>	<b>Omega-3 Group 34 weeks Mean (SD)</b>	<b>Control Group 34 weeks Mean (SD)</b>	<b>Omega-3 Group Effect*</b>	<b>Control Group Effect*</b>	<b>Difference**</b>	<b>Interaction P-value***</b>
<b>DHA</b>								
≤4.1%	2.03 (0.27)	1.98 (0.31)	2.81 (0.91)	1.96 (0.43)	0.77 (0.56, 0.99)	-0.02 (-0.11, 0.07)	0.80 (0.57, 1.03)	0.19
>4.1 - ≤4.9	2.50 (0.33)	2.52 (0.31)	3.20 (0.91)	2.35 (0.42)	0.71 (0.59, 0.83)	-0.17 (-0.22, -0.11)	0.87 (0.74, 1.01)	
>4.9%	3.21 (0.54)	3.26 (0.61)	3.64 (0.85)	2.67 (0.55)	0.43 (0.31, 0.54)	-0.59 (-0.66, -0.51)	1.01 (0.88, 1.15)	
<b>Free DHA</b>								
≤4.1%	0.84 (0.59)	0.72 (0.32)	0.59 (0.33)	0.39 (0.16)	-0.26 (-0.38, -0.14)	-0.33 (-0.39, -0.27)	0.07 (-0.07, 0.20)	0.06
>4.1 - ≤4.9	0.88 (0.48)	0.88 (0.44)	0.70 (0.40)	0.49 (0.20)	-0.17 (-0.25, -0.10)	-0.39 (-0.45, -0.34)	0.22 (0.13, 0.32)	
>4.9%	0.90 (0.46)	0.94 (0.44)	0.78 (0.40)	0.56 (0.25)	-0.12 (-0.19, -0.05)	-0.38 (-0.44, -0.33)	0.26 (0.17, 0.35)	
<b>4-HDHA</b>								
≤4.1%	20.04 (29.41)	13.33 (11.48)	10.35 (8.48)	7.41 (5.43)	-9.52 (-15.49, -3.54)	-5.93 (-8.19, -3.67)	-3.59 (-9.98, 2.80)	0.06
>4.1 - ≤4.9	18.79 (24.32)	17.88 (18.95)	13.73 (12.60)	9.44 (6.63)	-5.13 (-8.49, -1.77)	-8.47 (-10.95, -5.98)	3.34 (-0.85, 7.52)	
>4.9%	16.59 (14.23)	17.89 (14.31)	14.52 (13.58)	10.76 (8.13)	-1.96 (-4.42, 0.49)	-7.05 (-9.01, -5.09)	5.08 (1.93, 8.23)	
<b>7-HDHA</b>								
≤4.1%	0.96 (1.13)	0.85 (0.64)	0.83 (0.62)	0.59 (0.29)	-0.13 (-0.32, 0.06)	-0.26 (-0.38, -0.15)	0.13 (-0.09, 0.35)	0.02
>4.1 - ≤4.9	1.13 (1.83)	0.97 (0.80)	1.15 (1.04)	0.75 (0.39)	0.01 (-0.25, 0.27)	-0.23 (-0.33, -0.12)	0.24 (-0.04, 0.52)	
>4.9%	0.95 (0.67)	1.05 (0.68)	1.29 (0.97)	0.86 (0.46)	0.33 (0.19, 0.48)	-0.19 (-0.28, -0.09)	0.52 (0.35, 0.69)	
<b>14-HDHA</b>								
≤4.1%	6.18 (8.72)	5.65 (6.79)	5.51 (8.02)	3.16 (3.29)	-0.42 (-2.67, 1.84)	-2.53 (-4.03, -1.02)	2.11 (-0.61, 4.82)	0.27
>4.1 - ≤4.9								

<b>Baseline Omega-3<sup>†</sup> Status</b>	<b>Omega-3 Group Baseline Mean (SD)</b>	<b>Control Group Baseline Mean (SD)</b>	<b>Omega-3 Group 34 weeks Mean (SD)</b>	<b>Control Group 34 weeks Mean (SD)</b>	<b>Omega-3 Group Effect*</b>	<b>Control Group Effect*</b>	<b>Difference**</b>	<b>Interaction P-value***</b>
>4.9%	7.35 (5.98)	9.38 (10.46)	6.20 (5.39)	4.10 (3.37)	-1.13 (-2.11, -0.14)	-5.23 (-6.47, -4.00)	4.11 (2.53, 5.69)	
<b>19,20EpDPA</b>								
≤4.1%	0.24 (0.30)	0.18 (0.27)	0.31 (0.25)	0.19 (0.18)	0.05 (-0.01, 0.12)	-0.00 (-0.05, 0.05)	0.05 (-0.03, 0.14)	0.14
>4.1 - ≤4.9	0.25 (0.31)	0.26 (0.32)	0.45 (0.35)	0.30 (0.21)	0.18 (0.13, 0.24)	0.02 (-0.02, 0.07)	0.16 (0.09, 0.23)	
>4.9%	0.33 (0.42)	0.32 (0.33)	0.50 (0.39)	0.44 (1.49)	0.15 (0.09, 0.22)	0.11 (-0.09, 0.30)	0.04 (-0.16, 0.25)	
<b>Omega-3<sup>†</sup> fatty acids</b>								
≤4.1%	3.76 (0.34)	3.70 (0.36)	4.49 (1.06)	3.53 (0.85)	0.73 (0.47, 0.99)	-0.17 (-0.35, 0.01)	0.90 (0.59, 1.21)	0.15
>4.1 - ≤4.9	4.52 (0.23)	4.53 (0.22)	5.03 (1.17)	4.09 (0.74)	0.51 (0.35, 0.67)	-0.45 (-0.55, -0.35)	0.96 (0.77, 1.14)	
>4.9%	5.63 (0.70)	5.71 (0.79)	5.59 (1.10)	4.48 (0.74)	-0.04 (-0.20, 0.11)	-1.23 (-1.35, -1.12)	1.19 (0.99, 1.38)	
<b>Free Omega-3<sup>†</sup> fatty acids</b>								
≤4.1%	1.04 (0.73)	0.88 (0.39)	0.72 (0.39)	0.52 (0.21)	-0.31 (-0.46, -0.17)	-0.37 (-0.44, -0.29)	0.05 (-0.11, 0.21)	0.04
>4.1 - ≤4.9	1.08 (0.60)	1.09 (0.54)	0.89 (0.51)	0.63 (0.26)	-0.19 (-0.29, -0.10)	-0.45 (-0.52, -0.38)	0.26 (0.14, 0.38)	
>4.9%	1.10 (0.55)	1.15 (0.52)	0.97 (0.50)	0.73 (0.32)	-0.13 (-0.21, -0.04)	-0.42 (-0.49, -0.36)	0.30 (0.19, 0.40)	

DHA, docosahexaenoic acid;

<sup>†</sup>Omega-3, sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.

\* Values are estimated difference in the mean fatty acid or oxylipin concentrations (95% confidence interval) for 34 weeks' vs baseline adjusted for enrolment centre and recent omega-3 supplementation by baseline total omega-3 status. Positive values indicate fatty acid or oxylipin concentrations are increasing over time. Negative values indicate fatty acid or oxylipin concentrations are decreasing over time.

\*\* Values are estimated difference in the mean change in fatty acid or oxylipin concentrations over time (95% confidence interval) for omega-3 vs control adjusted for enrolment centre and recent omega-3 supplementation by baseline total omega-3 status.

\*\*\* P-value for the 3-way interaction between baseline omega-3 status, treatment group and time. Results should be interpreted with caution where the interaction is not statistically significant.

## REFERENCES

1. Middleton P, Gomersall JC, Gould JF, Shepherd E, Olsen SF, Makrides M. Omega-3 fatty acid addition during pregnancy. *Cochrane Database Syst Rev.* 2018;11(11):CD003402.
2. Samuel TM, Sakwinska O, Makinen K, Burdge GC, Godfrey KM, Silva-Zolezzi I. Preterm Birth: A Narrative Review of the Current Evidence on Nutritional and Bioactive Solutions for Risk Reduction. *Nutrients.* 2019;11(8):1811.
3. Yuan ZX, Majchrzak-Hong S, Keyes GS, Iadarola MJ, Mannes AJ, Ramsden CE. Lipidomic profiling of targeted oxylipins with ultra-performance liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem.* 2018;410(23):6009-29.
4. Gabbs M, Leng S, Devassy JG, Monirujjaman M, Aukema HM. Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. *Adv Nutr.* 2015;6(5):513-40.
5. Tessaro FH, Ayala TS, Martins JO. Lipid mediators are critical in resolving inflammation: a review of the emerging roles of eicosanoids in diabetes mellitus. *Biomed Res Int.* 2015;2015:568408.
6. Narumiya S, Furuyashiki T. Fever, inflammation, pain and beyond: prostanoid receptor research during these 25 years. *The FASEB Journal.* 2011;25(3):813-8.
7. Corsinovi L, Biasi F, Poli G, Leonarduzzi G, Isaia G. Dietary lipids and their oxidized products in Alzheimer's disease. *J Molecular nutrition food research.* 2011;55(S2):S161-SS72.
8. Amtul Z, Uhrig M, Wang L, Rozmahel RF, Beyreuther K. Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight. *Neurobiol Aging.* 2012;33(4):831 e21-31.
9. Allen KG, Harris MA. The role of n-3 fatty acids in gestation and parturition. *Experimental biology and medicine (Maywood, NJ).* 2001;226(6):498-506.
10. Keelan JA, Mas E, D'Vaz N, et al. Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors. 2015;149(2):171-8.
11. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. *Chem Rev.* 2011;111(10):5922-43.
12. Simmonds L.A STR, Skubisz M, Middleton P.F, Best K.P, Yelland L.N, Quinlivan J, Zhou S.J, Liu G, McPhee A.J, Gibson R.A, Makrides M. Omega-3 fatty acid supplementation in pregnancy – baseline omega-

- 3 status and early preterm birth: exploratory analysis of a randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2020.
13. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. *J Am Coll Cardiol*. 2011;58(20):2047-67.
  14. Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochim Biophys Acta*. 2015;1851(4):469-84.
  15. Buczynski MW, Dumlao DS, Dennis EA. Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. *J Lipid Res*. 2009;50(6):1015-38.
  16. Zhou SJ, Best K, Gibson R, et al. Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial. *BMJ Open*. 2017;7(9):e018360.
  17. Makrides M, Best K, Yelland L, et al. A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery. *N Engl J Med*. 2019;381(11):1035-45.
  18. Liu G, Muhlhausler BS, Gibson RA. A method for long term stabilisation of long chain polyunsaturated fatty acids in dried blood spots and its clinical application. *Prostaglandins Leukot Essent Fatty Acids*. 2014;91(6):251-60.
  19. Hewawasam E, Liu G, Jeffery DW, Muhlhausler BS, Gibson RA. A validated method for analyzing polyunsaturated free fatty acids from dried blood spots using LC-MS/MS. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 2017;125:1-7.
  20. Hewawasam E, Liu G, Jeffery DW, Muhlhausler BS, Gibson RA. A stable method for routine analysis of oxylipins from dried blood spots using ultra-high performance liquid chromatography-tandem mass spectrometry. *J Prostaglandins, Leukotrienes and Essential Fatty Acids*. 2018;137:12-8.
  21. Ramsden CE, Makrides M, Yuan Z-X, et al. Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth? *J Prostaglandins, Leukotrienes and Essential Fatty Acids*. 2020;153:102041.
  22. Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. *J Cochrane Database of Systematic Reviews*. 2014(6).



23. Olson DM, Ammann C. Role of the prostaglandins in labour and prostaglandin receptor inhibitors in the prevention of preterm labour. *Front Biosci.* 2007;12(1):1329-43.
24. Makrides M, Neumann MA, Gibson RA. Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. *Eur J Clin Nutr.* 1996;50(6):352-7.

5544 pregnancies underwent randomization

2770 pregnancies assigned to the  
omega-3 LCPUFA group

2774 pregnancies assigned to the  
control group

N=1382 pregnancies randomly selected from cohort for dry blood  
spot analysis to measure free fatty acids and oxylipins

671 omega-3 LCPUFA group  
pregnancies







711 control group pregnancies

57 pregnancies excluded  
- 10 not a singleton  
pregnancy  
- 47 no baseline DBS




62 pregnancies excluded  
- 10 not a singleton  
pregnancy  
- 52 no baseline DBS

614 pregnancies in analysis



649 pregnancies in analysis

















**Treatment Group** ● Control ● Omega-3









Treatment Group ● Control ● Omega-3



**Treatment Group** — Control — Omega-3



Treatment Group — Control — Omega-3



Treatment Group ● Control ● Omega-3